Add to ORKGSurfactant defi ciency in preterm babies causes respira-tory distress syndrome (RDS). This disease can now be successfully treated by airway instillation of exogenous surfactants and the best results have been obtained wit
Respiratory distress syndrome is pulmoner insufficiency caused by the lack of surfactant and the mai...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
Exogenous surfactant therapy has been recognised as an approach to alleviating the surfactant-defici...
Today, there is good evidence that neonatal respir-atory distress syndrome (RDS) can be prevented, t...
In the last 4 decades, advances in neonatology have led to a significant increase in the survival of...
Exogenous surfactant has been the primary life-saving therapy for respiratory distress syndrome (RDS...
Respiratory distress syndrome (RDS) is a common consequence of pulmonary immaturity in the lungs of ...
Our aim was to develop consensus recommendations from United Kingdom (UK) neonatal specialists on th...
premature infants with RDS Background. The significant advancement in the treatment of respiratory d...
To date three types of surfactant for replacement therapy have been developed: animal derived (or na...
Respiratory distress syndrome (RDS) caused by surfactant deficiency is major cause for neonatal mort...
Abstract: The key feature of respiratory distress syndrome (RDS) is the insufficient production of s...
Respiratory distress syndrome (RDS) is a major cause of neonatal mortality and morbidity, especially...
Objectives: Prematurity is one of the most important issues in perinatology. The most frequent postn...
International audienceSurfactant is not a new discovery in biology and medicine. In 1929, Neergard e...
Respiratory distress syndrome is pulmoner insufficiency caused by the lack of surfactant and the mai...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
Exogenous surfactant therapy has been recognised as an approach to alleviating the surfactant-defici...
Today, there is good evidence that neonatal respir-atory distress syndrome (RDS) can be prevented, t...
In the last 4 decades, advances in neonatology have led to a significant increase in the survival of...
Exogenous surfactant has been the primary life-saving therapy for respiratory distress syndrome (RDS...
Respiratory distress syndrome (RDS) is a common consequence of pulmonary immaturity in the lungs of ...
Our aim was to develop consensus recommendations from United Kingdom (UK) neonatal specialists on th...
premature infants with RDS Background. The significant advancement in the treatment of respiratory d...
To date three types of surfactant for replacement therapy have been developed: animal derived (or na...
Respiratory distress syndrome (RDS) caused by surfactant deficiency is major cause for neonatal mort...
Abstract: The key feature of respiratory distress syndrome (RDS) is the insufficient production of s...
Respiratory distress syndrome (RDS) is a major cause of neonatal mortality and morbidity, especially...
Objectives: Prematurity is one of the most important issues in perinatology. The most frequent postn...
International audienceSurfactant is not a new discovery in biology and medicine. In 1929, Neergard e...
Respiratory distress syndrome is pulmoner insufficiency caused by the lack of surfactant and the mai...
In the last decade there has been growing insight into surfactant function and metabolism and on how...
Exogenous surfactant therapy has been recognised as an approach to alleviating the surfactant-defici...